HER2 Low-Amplified Breast Cancer: The Efficacy of Anti-HER2 Therapy in Neoadjuvant Setting

被引：0
|
作者：
Lv, Hong [1 ]
Bai, Qianming [1 ]
Shui, Ruohong [1 ]
Xu, Xiaoli [1 ]
Yu, Bao-Hua [1 ]
Bi, Rui [2 ]
Cheng, Yufan [1 ]
Tu, Xiaoyu [1 ]
Zhou, Xiaoyan [2 ]
Yang, Wentao [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Shanghai, Peoples R China
来源：
LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
187
引用
收藏
页码：S177 / S178
页数：2
相关论文
共 50 条
  • [31] HER2 Intratumoral Heterogeneity Is Associated with Incomplete Response to Anti-HER2 Neoadjuvant Chemotherapy in HER2-Positive Breast Carcinoma
    Li, Zaibo
    Nitta, Hiroaki
    Hou, Yanjun
    Banks, Peter
    [J]. LABORATORY INVESTIGATION, 2017, 97 : 55A - 55A
  • [32] Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns
    Lv, Hong
    Bai, Qian-Ming
    Li, Ming
    Cai, Meng-Yuan
    Zhou, Shu-Ling
    Liu, Yin
    Wang, Zhong-Hua
    Shui, Ruo-Hong
    Lu, Hong-Fen
    Xu, Xiao-Li
    Yu, Bao-Hua
    Tu, Xiao-Yu
    Bi, Rui
    Cheng, Yu-Fan
    Zhou, Xiao-Yan
    Shao, Zhi-Min
    Yang, Wen-Tao
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2024,
  • [33] HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome
    Bottosso, Michele
    Sandoval, Renata Lazari
    Verret, Benjamin
    Polidorio, Natalia
    Caron, Olivier
    Gennari, Alessandra
    Bychkovsky, Brittany
    Hyman, Sophie
    Achatz, Maria Isabel
    Guarneri, Valentina
    Andre, Fabrice
    Garbe, Judy
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [34] HER2 Intratumoral Heterogeneity Is Associated with Incomplete Response to Anti-HER2 Neoadjuvant Chemotherapy in HER2-Positive Breast Carcinoma
    Li, Zaibo
    Nitta, Hiroaki
    Hou, Yanjun
    Banks, Peter
    [J]. MODERN PATHOLOGY, 2017, 30 : 55A - 55A
  • [35] HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome
    Bottosso, Michele
    Sandoval, Renata L.
    Verret, Benjamin
    Polidorio, Natalia
    Caron, Olivier
    Gennari, Alessandra
    Bychkovsky, Brittany L.
    Cahill, Sophie H.
    Achatz, Maria I.
    Guarneri, Valentina
    Andre, Fabrice
    Garber, Judy E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 211
  • [36] Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
    Giugliano, Federica
    Carnevale Schianca, Ambra
    Corti, Chiara
    Ivanova, Mariia
    Bianco, Nadia
    Dellapasqua, Silvia
    Criscitiello, Carmen
    Fusco, Nicola
    Curigliano, Giuseppe
    Munzone, Elisabetta
    [J]. CANCERS, 2023, 15 (05)
  • [37] Deregulation of HER2 Downstream Signaling in Breast Cancer Cells by a Cocktail of Anti-HER2 scFvs
    Nejatollahi, Foroogh
    Ranjbar, Reza
    Younesi, Vahid
    Asgharpour, Mahdi
    [J]. ONCOLOGY RESEARCH, 2012, 20 (08) : 333 - 340
  • [38] The HER2 CISH pharmDx™ Kit in the assessment of breast cancer patients for anti-HER2 treatment
    Foged, Niels T.
    Brugmann, Anja
    Jorgensen, Jan T.
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2013, 13 (03) : 233 - 242
  • [39] Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer
    Matthew Loft
    Sheau Wen Lok
    Richard De Boer
    Laeeq Malik
    Sally Greenberg
    Belinda Yeo
    Angelyn Anton
    Michelle Nottage
    Vanessa Wong
    Louise Nott
    Ian M. Collins
    Javier Torres
    Frances Barnett
    Janine M. Lombard
    Peter Gibbs
    Lucy Gately
    [J]. Breast Cancer Research and Treatment, 2023, 198 : 67 - 74
  • [40] Prospect for anti-HER2 receptor therapy in breast cancer
    Brand, FX
    Ravanel, N
    Gauchez, AS
    Pasquier, D
    Payan, R
    Fagret, D
    Mousseau, M
    [J]. ANTICANCER RESEARCH, 2006, 26 (1B) : 463 - 470
12345